People with HIV who have belly fat and are on medication to control the virus who took tesamorelin did not show a significant improvement in thinking skills compared to those who received usual care after six months. This finding is from the abstract summary - full study details were not available

Scientific Claim

In virally suppressed, abdominally obese individuals with HIV, tesamorelin treatment is not associated with a statistically significant improvement in neurocognitive performance compared to standard of care after 6 months (between-group P=0.673).

Original Statement

“but the between-group difference was not significant (P = .673).”

From study:Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study design allows for association claims, and the abstract clearly states the between-group difference was not significant, so the claim appropriately uses 'not associated with a statistically significant improvement'.

Evidence from Studies

Supporting (1)

Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.

Randomized Controlled Trial

Human

2025 Jun 2

Contradicting (0)

No contradicting evidence found

Source Study

Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.

Score: 62

DOI: 10.1093/infdis/jiaf012

Similar Assertions

In people with HIV who have belly fat and are on medication to control the virus, changes in IGF-1 levels from tesamorelin treatment did not relate to changes in thinking skills or waist size. This finding is from the abstract summary - full study details were not available

80%

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had a waist size that was about 2.7 centimeters smaller on average compared to those who didn't, and this difference was statistically significant. This finding is from the abstract summary - full study details were not available

78%

HIV patients with belly fat who took tesamorelin were more likely to lose at least 8% of their visceral fat than those who took a placebo.

75%

If the drug doesn’t shrink your belly fat by at least 8%, it won’t make your fat look healthier on scans — you have to respond to the drug for this benefit.

73%

HIV patients with belly fat who took tesamorelin had a 69% chance of losing at least 8% visceral fat, while those on placebo had only a 33% chance, showing a clear benefit from the drug.

73%